-
Subject Areas on Research
-
A clinical cardiology perspective of thrombophilias.
-
Adverse effects of corticosteroids on the cardiovascular system.
-
Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8.
-
Anticoagulants in pregnancy.
-
Antiplatelet therapy in pediatric cardiovascular patients.
-
Atherothrombotic disorders: new insights from hematology.
-
COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations.
-
Characteristics of abdominal vein thrombosis in children and adults.
-
Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.
-
Characterization of the hypercoagulable state in patients with sickle cell disease.
-
Clinical and laboratory evaluation of thrombophilia.
-
Clinical causes and treatment of the thrombotic storm.
-
Coagulation abnormalities in patients with hip osteonecrosis.
-
Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass.
-
Coagulation disorders and their cutaneous presentations: Pathophysiology.
-
Coagulopathy of Coronavirus Disease 2019.
-
Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis.
-
Cutaneous collagenous vasculopathy in a middle-aged woman with a history of prothrombin G20210A thrombophilia.
-
Depression and cardiovascular disease: mechanisms of interaction.
-
Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation.
-
Diagnostic and Therapeutic Challenges.
-
Do East Asians have different hypercoagulable states compared with Western population?
-
Does Anticoagulation Improve Flap Outcomes in Hypercoagulable Patients? A Systematic Review.
-
Dysregulation of hemostasis by cancer.
-
Effects of inherited thrombophilic mutations in an adolescent with antiphospholipid syndrome and systemic lupus erythematosus.
-
Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk.
-
Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation.
-
Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia.
-
Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020.
-
Excess factor VIII and hypercoagulability.
-
Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.
-
High altitude: a hypercoagulable state: results of a prospective cohort study.
-
Hypercoagulability - The Underdiagnosed and Undertreated Nemesis of Congenital Heart Surgery.
-
Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass.
-
Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms.
-
Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study.
-
Hypercoagulable states in cardiovascular disease.
-
Hypercoagulable states: a review.
-
Hypercoagulation and thrombophilia in liver disease.
-
Infant cardiopulmonary bypass: a procoagulant state.
-
Inherited thrombophilia in childhood arterial stroke: data from Lebanon.
-
Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology.
-
Microparticles from stored red blood cells promote a hypercoagulable state in a murine model of transfusion.
-
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
-
Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review.
-
Perioperative Management of the Gynecologic Patient on Long-term Anticoagulation.
-
Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry.
-
Physiologic and biochemical rationale for treating COVID-19 patients with hyperbaric oxygen.
-
Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction.
-
Pregnancy-associated thrombosis.
-
Prenatal screening for thrombophilia: the background and the approach.
-
Prevention and treatment of venous thromboembolism in pregnancy.
-
Prevention of venous thromboembolism in pregnancy: a review of guidelines, 2000-2011.
-
Regulatable aptamers in medicine: focus on antithrombotic strategies.
-
Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis.
-
SARS-CoV-2 and Stroke in a New York Healthcare System.
-
Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.
-
Screening for hypercoagulable syndromes following stroke.
-
Sickle cell disease is associated with iron mediated hypercoagulability.
-
Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study.
-
Temporal trends in maternal medical conditions and stillbirth.
-
The U.S. Thrombosis and Hemostasis Centers pilot sites program.
-
The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event.
-
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management.
-
The scientific basis for evaluation and management of thrombotic disorders.
-
The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
-
Thromboembolism in pregnancy: recurrence risks, prevention and management.
-
Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?
-
Thromboinflammation and the hypercoagulability of COVID-19.
-
Thrombophilia screening in asymptomatic children.
-
Thrombophilias and recurrent miscarriage.
-
Thrombophilias: when should we test and how does it help?
-
Thrombosis during pregnancy and the postpartum period.
-
Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.
-
Thrombotic preparedness in aging: a translatable construct for thrombophilias?
-
Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group.
-
Tissue factor and fibrin in tumor angiogenesis.
-
Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure.
-
[Hematologic diseases: from within the heart].
-
[Recent advances in atherothrombotic diseases].
-
Keywords of People
-
O'Connor, Christopher Michael,
Adjunct Professor in the Department of Medicine,
Medicine, Clinical Pharmacology
-
Schanberg, Laura Eve,
Professor of Pediatrics,
Pediatrics, Rheumatology
-
Shah, Nirmish Ramesh,
Associate Professor of Medicine,
Medicine, Hematology